Skip to search boxSkip to navigationSkip to main content

CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer

  • Xiurong Li
    ,
  • ,
  • Khalid Sossey-Alaoui(corresponding author)
*Corresponding author for this work
  • Roswell Park Cancer Institute
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumor-igenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoter-associated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1474-1480 (7 pages)

Journal (Volume, Issue Number)

Oncogene (Volume 23, Issue 7)

Publication milestones

  • Published - 02/19/2004

Publication status

Published - 02/19/2004

ISSN

0950-9232

Publication IDs

  • Scopus: 1442308340
  • PubMed: 14973555

Publication metrics

Metrics

Scopus
citations
SciVal
citations
42
Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
SciVal
FWCI
0.43
SciVal
Author count
3
SciVal
Paper percentile
83

PlumX, opens in new tab

Captures
22
Citation count
52

Funding Details

We thank Dr Harold Asch for kindly providing the breast tumour samples; Natacha Diaz Meyer for helpful input; Michelle Detwiller, MS and Shakeeba Waseh, BS for their technical assistance. This work was supported in part by a grant (DAMD17-98-1-8294) from the United States Department of Defense (to JKC), by an Institutional Research Grant (IRG-02-197-01) from the American Cancer Society (to KSA), by a Cancer Center Support Grant (CA16056) from the National Cancer Institute (to Roswell Park Cancer Institute).
FundersFunding numbers
National Cancer Institute Cancer Center Support
-
DOD
IRG-02-197-01
ACS
-
NCI
P30CA016056